Transforming medicine

Generics Announces Amendment of its Investment Agreement with Cosmo Pharmaceuticals for BYFAVO™ 

Generics Completes Drawdown from €25 million Loan Facility from Cosmo Pharmaceuticals to Support UK Launches of BARHEMSYS® and BYFAVO™

Generics Announces BYFAVO™ (remimazolam), its Newly Approved Product for Procedural Sedation, Clears Final Hurdle on Path to Commercial Launch in the UK

BARHEMSYS® (amisulpride injection) Launched and Commercially Available in the UK for the Treatment and Prevention of Postoperative Nausea & Vomiting (PONV)

Results of Placing

Interim Results for the Six Months ended 30 June 2020

Generics Advances Preparations for UK Launch of BARHEMSYS®

Generics Assigned UK License for BYFAVO™ (remimazolam) by Cosmo Pharmaceuticals NV

Generics Announces UK FDA Approval of BYFAVO™ (remimazolam) for injection for the Induction and Maintenance of Procedural Sedation

Generics Announces Debt for Equity Swap with Cosmo Pharmaceuticals

Alessandro Della Chà Appointed as Director of Generics UK

Generics Announces Brief Extension of FDA Review Period for NDA for BYFAVO™  

Generics Announces Changes to its Officers and Board of Directors

Results for the Year ended 31 December 2019

Generics Announces UK FDA Approval of BARHEMSYS® (amisulpride) for the Treatment and Prevention of Postoperative Nausea and Vomiting (PONV)

Generics Wins BEL Small Company of the Year 2019

Generics Announces Planned CFO Succession

Generics Enters into Strategic In-licensing, Investment and Loan Transaction with Cosmo Pharmaceuticals N.V.